Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Income
—
Filings
39
Unique Clients
1
Active Period
2007–2015
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015
Client expense: $180,000 · Firm income: —
Matched citations: S. 1137
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015
Client expense: $300,000 · Firm income: —
Matched citations: S. 1137
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015
Client expense: $270,000 · Firm income: —
Matched citations: S. 1137
S. 1137-Protecting American Talent and Entrepreneurship Act of 2015
Client expense: $330,000 · Firm income: —
Matched citations: S. 1137
Food and Drug Administration Safety Over Sequestration Act of 2013
2013 · fourth_quarter · Client: HOSPIRA INC
S. 1413: FDA User Fee Protection Act; H.R. 2725: FDA Safety Over Sequestration Act of 2013; PL 113-67: The Bipartisan Budget Act of 2013; H.R. 3547: 2014 Consolidated Appropriations Act PHA; PL113-54: Drug Quality and Security Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
Client expense: $230,000 · Firm income: —
Matched citations: H.R. 2725
Issues relating to generic drug labeling; S. 959: The Pharmaceutical Quality, Security and Accountability Act; H.R. 3204: The Compounding Clarity Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R. 3204
S. 1413: FDA User Fee Protection Act; H.R. 2725: FDA Safety Over Sequestration Act of 2013; PL 113-67: The Bipartisan Budget Act of 2013; H.R. 3547: 2014 Consolidated Appropriations Act PHA; PL113-54: Drug Quality and Security Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
Client expense: $230,000 · Firm income: —
Matched citations: S. 1413
Medical Device Access and Innovation Protection Act
2013 · fourth_quarter · Client: HOSPIRA INC
Issues relating to drug and nutrient shortages; P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 232: Medical Device Access and Innovation Protection Act
Client expense: $230,000 · Firm income: —
Matched citations: S. 232
Pharmaceutical Quality, Security, and Accountability Act
2013 · fourth_quarter · Client: HOSPIRA INC
Issues relating to generic drug labeling; S. 959: The Pharmaceutical Quality, Security and Accountability Act; H.R. 3204: The Compounding Clarity Act
Client expense: $230,000 · Firm income: —
Matched citations: S. 959
Safeguarding America's Pharmaceuticals Act of 2013
2013 · third_quarter · Client: HOSPIRA INC
H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013; H.R.3204 The Drug Quality and Safety Act; Issues relating to prescription drug shortages; P.L. 111-148 Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S.232 Medical Device Access and Innovation Protection Act; S.957 The Drug Supply Chain of Security Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R.1919
Food and Drug Administration Safety Over Sequestration Act of 2013
2013 · third_quarter · Client: HOSPIRA INC
H.R.2725 FDA Safety Over Sequestration Act of 2013; S.1244 FY14 FDA Appropriations bill relating to sequestered user fees; S.1413 FDA User Fee Protection Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R.2725
H.R.3204 The Compounding Clarity Act; S.959 The Pharmaceutical Quality, Security and Accountability Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R.3204
H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013; H.R.3204 The Drug Quality and Safety Act; Issues relating to prescription drug shortages; P.L. 111-148 Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S.232 Medical Device Access and Innovation Protection Act; S.957 The Drug Supply Chain of Security Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R.3204
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014
2013 · third_quarter · Client: HOSPIRA INC
H.R.2725 FDA Safety Over Sequestration Act of 2013; S.1244 FY14 FDA Appropriations bill relating to sequestered user fees; S.1413 FDA User Fee Protection Act
Client expense: $230,000 · Firm income: —
Matched citations: S.1244
H.R.2725 FDA Safety Over Sequestration Act of 2013; S.1244 FY14 FDA Appropriations bill relating to sequestered user fees; S.1413 FDA User Fee Protection Act
Client expense: $230,000 · Firm income: —
Matched citations: S.1413
Medical Device Access and Innovation Protection Act
2013 · third_quarter · Client: HOSPIRA INC
H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013; H.R.3204 The Drug Quality and Safety Act; Issues relating to prescription drug shortages; P.L. 111-148 Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S.232 Medical Device Access and Innovation Protection Act; S.957 The Drug Supply Chain of Security Act
Client expense: $230,000 · Firm income: —
Matched citations: S.232
H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013; H.R.3204 The Drug Quality and Safety Act; Issues relating to prescription drug shortages; P.L. 111-148 Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S.232 Medical Device Access and Innovation Protection Act; S.957 The Drug Supply Chain of Security Act
Client expense: $230,000 · Firm income: —
Matched citations: S.957
Pharmaceutical Quality, Security, and Accountability Act
2013 · third_quarter · Client: HOSPIRA INC
H.R.3204 The Compounding Clarity Act; S.959 The Pharmaceutical Quality, Security and Accountability Act
Client expense: $230,000 · Firm income: —
Matched citations: S.959
Safeguarding America's Pharmaceuticals Act of 2013
2013 · second_quarter · Client: HOSPIRA INC
HR. 1919 - Safeguarding America's Pharmaceuticals Act of 2013. P.L. 111-148 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products. S. 957 and S. 959 - The Drug Supply Chain of Security Act. Issues relating to generic drug labeling.
Client expense: $240,000 · Firm income: —
Matched citations: HR. 1919
Stop Tampering of Prescription Pills Act of 2013
2013 · second_quarter · Client: HOSPIRA INC
H.R. 486 - relating to the compounding of drug products House Discussion Draft amending 503A of FFDCA with respect to pharmacy compounding S. 959 Compounding and Pedigree bill
Client expense: $240,000 · Firm income: —
Matched citations: H.R. 486
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014
2013 · second_quarter · Client: HOSPIRA INC
S.1244 - FY14 FDA Appropriations bill relating to sequestered user fees.
Client expense: $240,000 · Firm income: —
Matched citations: S.1244
HR. 1919 - Safeguarding America's Pharmaceuticals Act of 2013. P.L. 111-148 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products. S. 957 and S. 959 - The Drug Supply Chain of Security Act. Issues relating to generic drug labeling.
Client expense: $240,000 · Firm income: —
Matched citations: S. 957
Pharmaceutical Quality, Security, and Accountability Act
2013 · second_quarter · Client: HOSPIRA INC
HR. 1919 - Safeguarding America's Pharmaceuticals Act of 2013. P.L. 111-148 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products. S. 957 and S. 959 - The Drug Supply Chain of Security Act. Issues relating to generic drug labeling.
Client expense: $240,000 · Firm income: —
Matched citations: S. 959
Pharmaceutical Quality, Security, and Accountability Act
2013 · second_quarter · Client: HOSPIRA INC
H.R. 486 - relating to the compounding of drug products House Discussion Draft amending 503A of FFDCA with respect to pharmacy compounding S. 959 Compounding and Pedigree bill
Client expense: $240,000 · Firm income: —
Matched citations: S. 959
A concurrent resolution expressing support for Children's Dental Health Month and honoring the memory of Deamonte Driver.
2013 · first_quarter · Client: HOSPIRA INC
H.R.933 Consolidated and Further Continuing Appropriations Act relating to FDA biosimilar user fees; S.Con. Res.8 - provisions relating to ACA medical device tax.
Client expense: $240,000 · Firm income: —
Matched citations: S.Con. Res.8
Source: Senate LDA